Though interest in robotics is high in Europe, much of the commercial opportunity will likely fall to two small US companies who are just now aggressively spreading the gospel of robotics through affiliations with minimally-invasive surgery pioneers. That's not to say that European companies are standing idly by: Germany's Maquet is pushing forward with an orthopedic robot. Many obstacles to adoption remain for robots, but the high cost of these units may not be as much of a problem as might be expected. The goal--and challenge--for robotic companies and their clinical advocates: to firmly establish computer-assisted surgery as an important new platform and clinical advance in surgical practice.
by David Cassak
Part II of a two part-series
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.
Medtronic held its grip on first place in the 2024 global medical device and diagnostics rankings after losing it two years ago to Abbott, which is now in third place behind fast-rising, acquisitive Johnson & Johnson MedTech.
A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.
